Careers  |  Sign In  |  Register

Gene Identified That Increases Risk for Developing Neuropathy After Taking Vincristine

The JAMA Report

Patients diagnosed with Acute Lymphoblastic Leukemia, the most common form of childhood cancer, are typically given Vincristine, a very powerful chemotherapy drug with a high toxicity called neuropathy that causes patients to become very weak in their ankles and feet. Many of these patients find it difficult to move or lift their feet up and end up needing braces to provide support. New research has found a gene that increases the risk for developing neuropathy by up to three times, with twice the severity as other patients. Researchers are working on ways to lower the dose of Vincristine in order to lower the risk of neuropathy without compromising the success of the therapy.